Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis

Overview of attention for article published in OncoTargets and therapy, June 2018

Altmetric Badge

Mentioned by

reddit: 1 Redditor

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 18 Mendeley

Summary Reddit Dimensions citations

So far, Dimensions has found 5 publications that cite this research output.

5

The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.

Factors associated with outcomes of second-line treatment for EGFR-mutant non-small-cell lung cancer patients after progression on first- or second-generation EGFR-tyrosine kinase inhibitor treatment

Article in Frontiers in Oncology (June 2023)

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan

Article in Targeted Oncology (February 2023)

Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma

Article in Oncology Letters (September 2022)